RT - Journal Article T1 - The Role of Aptamers in the Treatment of Glioblastoma Multiform JF - The-Neuroscience-Journal-of-Shefaye-Khatam YR - 2019 JO - The-Neuroscience-Journal-of-Shefaye-Khatam VO - 7 IS - 1 UR - http://shefayekhatam.ir/article-1-1866-en.html SP - 91 EP - 105 K1 - Glioblastoma K1 - Aptamers K1 - Nucleotide K1 - Oligodendroglia AB - Introduction: Glioblastoma multiform (GBM) or grade IV glioma is the most common and aggressive primary human brain tumor. Primary GBMs which arise spontaneously from glial cells and represent the vast majority of GBM are usually related to epidermal growth factor receptor amplification and mutations, deletion of phosphatase and tensin homolog (PTEN) on chromosome 10, p16 deletion, and TERT promoter mutation. Despite advances in treatment over the past few decades the median survival time of GBM patients is 12.1-14.6 months after diagnosis and only 3-5% of patients survive longer than 3 years. The effect of usual treatments, including surgery, radiotherapy, chemotherapy, and a combination of radiotherapy and chemotherapy, have extremely low effectiveness. Although surgery and temozolomide application during and after radiotherapy increases patient survival time, they have various side effects. Therefore, introducing a novel drug that able to inhibit GBM cell growth, proliferation, migration, and invasion is required. Since cancer cells have surface molecules that are over-expressed or altered, the molecular structures called aptamers have been designed using systematic evolution of ligands by exponential enrichment (SELEX) process to target these surface molecules. To date, several aptamers with advantages and disadvantages have been applied for the treatment of different diseases, including cancer, that are discussed in this study. Conclusion: Several aptamers with high capacity in the detection of GBM have been recently designed using the SELEX process that shows the high potential of aptamers in the management of GBM. LA eng UL http://shefayekhatam.ir/article-1-1866-en.html M3 10.29252/shefa.7.1.91 ER -